Stereotactic Radiosurgery Dose Reduction for Patients With Brain Metastases From Non–Small Cell Lung Primary on Immunotherapy or Targeted Therapy
In the contemporary era, RD SRS delivered concurrently with immunotherapy or targeted therapy may lower AREs without compromising local control to treat NSCLC brain metastases.
Authors
- Ryan D. Gentzler (ORCID: https://orcid.org/0000-0002-8983-6677)
- Camilo E. Fadul (ORCID: https://orcid.org/0000-0001-7459-7661)
- Jack Guiry
- David R. Penberthy
- Jason P. Sheehan (ORCID: https://orcid.org/0000-0002-4763-7346)
- Bardia Hajikarimloo (ORCID: https://orcid.org/0000-0001-8801-1158)
- Georgios Mantziaris (ORCID: https://orcid.org/0000-0002-3389-8836)
- Yuki Shinya (ORCID: https://orcid.org/0000-0003-0097-5804)
- Zhiyuan Xu (ORCID: https://orcid.org/0000-0001-9682-8029)
- Tanvika Vegiraju
- Abhinav Kareddy
- Salem M. Tos
- Jared H. Chung
- Edward Llinas
Institutions
- University of Virginia Health System (US)
- University of Virginia (US)
Publication Details
- Journal
- Neurosurgery
- Published
- 2026-02-12
- DOI
- https://doi.org/10.1227/neu.0000000000003961
- Primary Topic
- Brain Metastases and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00